Business
TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development
TiumBio (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable disease, announced today that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist.
About this update from Tiumbio Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) in China","length":195,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":195,"olType":false},{"type":"text","content":"SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable disease, announced today that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist.","length":421,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/TiumBio)","displaySize":"","headline":null,"caption":"(PRNewsfoto/TiumBio)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":167,"url":"https://media.zenfs.com/en/prnewswire.com/d564600e3d5ca4d6c2b423c122fd83f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mv87UWHE0qRH4lOXLDmDzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d564600e3d5ca4d6c2b423c122fd83f4","width":400,"height":167}},"href":"https://mma.prnewswire.com/media/2308813/tiumbio_logo_horizontal_c__7_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hansoh Pharma recently received approval for an IND (Investigational New Drug) application targeting ART, expanding the development area of merigolix.","length":155,"tagName":"p"},{"type":"text","content":"COS has been an integral part of ART treatment cycles. Availability of different gonadotropins for ovarian stimulation and gonadotropin releasing hormone (GnRH) analogues for prevention of premature rise of LH during follicular phase offer an opportunity for a successful outcome in women with different subsets of ovarian response.","length":337,"tagName":"p"},{"type":"text","content":"Orally administered merigolix may be important in the control of premature endogenous LH surge and in reducing the cycle cancellation rate, with an improvement of pregnancy rate per cycle. Currently, in COS regimens, gonadotropin-releasing hormone (GnRH) products are only available in injectable for...